ClinVar Miner

Submissions for variant NM_004239.4(TRIP11):c.5234A>G (p.Glu1745Gly)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 3
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Labcorp Genetics (formerly Invitae), Labcorp RCV003505497 SCV004250320 uncertain significance Achondrogenesis, type IA 2023-10-16 criteria provided, single submitter clinical testing This sequence change replaces glutamic acid, which is acidic and polar, with glycine, which is neutral and non-polar, at codon 1745 of the TRIP11 protein (p.Glu1745Gly). This variant is present in population databases (rs142300046, gnomAD 0.03%). This variant has not been reported in the literature in individuals affected with TRIP11-related conditions. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt TRIP11 protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.
Ambry Genetics RCV004963683 SCV005520972 uncertain significance Inborn genetic diseases 2024-10-25 criteria provided, single submitter clinical testing The c.5234A>G (p.E1745G) alteration is located in exon 16 (coding exon 16) of the TRIP11 gene. This alteration results from a A to G substitution at nucleotide position 5234, causing the glutamic acid (E) at amino acid position 1745 to be replaced by a glycine (G). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear.
PreventionGenetics, part of Exact Sciences RCV003901101 SCV004716049 uncertain significance TRIP11-related disorder 2024-01-11 no assertion criteria provided clinical testing The TRIP11 c.5234A>G variant is predicted to result in the amino acid substitution p.Glu1745Gly. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.024% of alleles in individuals of African descent in gnomAD. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.